June 14, 2004 – LAWFUEL – CMS Cameron McKenna has been advising Pfizer on the sale of a portfolio of 60 European over-the-counter (OTC) and personal care brands for a cash consideration of €135m (approximately US$163m). The transaction is expected to complete at or shortly after the end of June 2004.
The portfolio of brands is concentrated in certain therapeutic areas, principally skincare (medicated and cosmetic), haircare, women’s health, head lice treatment and upper respiratory tract, and incorporated some of the leading brands, including TCP Ô.
This sale is part of Pfizer’s strategy to sharpen its focus in Europe on its core brands that have strong regional and global growth potential.
CMS Cameron McKenna has been working with Pfizer since its merger with Warner-Lambert Company in June 2000, and previously was adviser to Warner-Lambert. The transaction team was led by Michael Draper (Corporate partner) and supported by Simon Vere Nicoll (Senior corporate solicitor), Sarah Hanson (Senior corporate solicitor), James Sparkes (Corporate solicitor), Matthew Willoughby (Corporate solicitor), John Armstrong (Technology partner), Yuban Moodley (Senior technology solicitor) and John Naccarato (Banking partner). The cross-practice team was further supported by legal experts from CMS Hasche Sigle (Germany), CMS Bureau Francis Lefebvre (France) and CMS Adonnino Ascoli & Cavasola Scamoni (Italy).
Michael Draper commented, “We are delighted to have assisted Pfizer in disposing of these assets on a challenging timescale. This was only possible because of an excellent working relationship with the in-house team at Pfizer.”